HOME >> BIOLOGY >> NEWS
Drug developed for rare disease may help millions more as treatment for cancer, autoimmune diseases

ANN ARBOR, Mich. An anti-angiogenesis drug developed at the University of Michigan is showing promise in studies of three different disease families, including multiple forms of cancer. The drug, tetrathiomolybdate or TM, essentially wages war against copper, which serves to choke off tumor growth, fibrosis and inflammation.

U-M researcher George Brewer, M.D., who developed the drug, will present his findings to date and report on ongoing basic and clinical TM research at the 226th American Chemical Society national meeting Sept. 10 in New York. Brewer's presentation will be part of a one-day symposium on medicinal inorganic chemistry.

TM began as a treatment for Wilson's disease, a rare genetic disease that causes toxic build-ups of copper. Recent phase III clinical data show TM is more effective than other treatments at reducing the disease's effects. Realizing the key role of copper in angiogenesis, Brewer and colleagues then began exploring treatments for cancer, including breast cancer, kidney cancer and liver cancer. Currently, TM is involved in nine phase II clinical studies related to cancer, with more planned.

But it doesn't end there. Brewer and colleagues are also looking into the effect of TM on inflammatory fibrosis diseases such as pulmonary fibrosis, cirrhosis, cystic fibrosis and psoriasis.

"TM has the potential to be a powerful tool in fighting a wide range of diseases. While it has literally saved the lives of young people with Wilson's disease, Wilson's is a rare disease. If early results in cancer and inflammatory diseases hold their promise through the next phase of trials, there's potential for this to impact a lot of people," says Brewer, Morton S. and Henrietta K. Sellner Emeritus Professor of Human Genetics at the University of Michigan Medical School.

Wilson's disease typically strikes young adults in their teens or early 20s. The condition causes copper to accumulate in the body at dangerous levels,
'"/>

Contact: Nicole Fawcett
nfawcett@umich.edu
734-764-2220
University of Michigan Health System
10-Sep-2003


Page: 1 2 3 4

Related biology news :

1. Computer database being developed at Temple will allow for better inventory of chemicals
2. New software developed at Rensselaer predicts promising ingredients for new drugs
3. New imaging technique developed to identify breast cancer
4. Portable kidney dialysis machine developed
5. New method of identifying and isolating stem cells developed
6. Study calls for cheaper antitoxins for plant poisoning in less-developed countries
7. Fe-TAML(R) activators developed at Carnegie Mellon remove recalcitrant sulfur from automotive fuels
8. Fe-TAML(R) activators developed at Carnegie Mellon decontaminate anthrax simulant
9. Fe-TAML(R) activators developed at Carnegie Mellon break down toxic pesticides
10. Fe-TAML(R) activators developed at Carnegie Mellon help cleanup paper and wood pulp manufacturing
11. Fe-TAML(R) activators developed at Carnegie Mellon decolorize textile mill wastewater

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:4/6/2017)... 2017 Forecasts by Product Type ... by End-Use (Transportation & Logistics, Government & Public Sector, ... Fossil Generation Facility, Nuclear Power), Industrial, Retail, Business Organisation ... Are you looking for a definitive report on the ... ...
(Date:4/3/2017)... 3, 2017  Data captured by IsoCode, ... detected a statistically significant association between the ... treatment and objective response of cancer patients ... predict whether cancer patients will respond to ... well as to improve both pre-infusion potency testing ...
(Date:3/28/2017)... PUNE, India , March 28, 2017 ... (Analog, IP, Biometrics), Hardware (Camera, Monitors, Servers, Storage Devices), ... Maintenance), Vertical, and Region - Global Forecast to 2022", ... 30.37 Billion in 2016 and is projected to reach ... 15.4% between 2017 and 2022. The base year considered ...
Breaking Biology News(10 mins):
(Date:5/22/2017)... , ... May 22, 2017 , ... ... with other leaders of the Maryland Biohealth community in developing and issuing recommendations ... Top 3 U.S. BioHealth Innovation Hub by 2023. , The ...
(Date:5/21/2017)... (PRWEB) , ... May 20, 2017 , ... ... that helps avoid the lengthy trial and error process by finding the right ... It can also strengthen the doctor-patient relationship through a personalized approach to treatment. ...
(Date:5/18/2017)... ... May 18, 2017 , ... ... April 28, 2017 at the Prince Of Wales Private Hospital. The procedure was ... level C6-C7. The patient failed conservative treatments prior to undergoing surgery. , The ...
(Date:5/18/2017)... ... 17, 2017 , ... NDA Partners Chairman Carl Peck, MD , announced ... Laboratories and President of Pharmaceutical Development Business Unit of Cardinal Health, has joined the ... Health, he was former Chief Operating Officer at Anaborex, Senior VP and General Manager ...
Breaking Biology Technology:
Cached News: